Bausch + Lomb Corporation - Çeyreklik Finansal İstatistikler (NYSE:BLCO) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit 22 M-25 M35 M137 M136 M 283 M Yatırım faaliyetlerinden elde edilen nakit -185 M-116 M-90 M-61 M-188 M -455 M Finansman faaliyetlerinden elde edilen nakit 146 M31 M90 M-12 M116 M 225 M Free cash flow -70 M-135 M-54 M63 M60 M -66 M

Haberler

Bausch + Lomb’a cerrahi cihaz için FDA onayı

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios - Slideshow (NYSE:BLCO) 2026-03-23

Bausch + Lomb’un glokom denemesi ELIOS için olumlu sonuçlar verdi

RBC, rakip gecikmesi sonrası Bausch & Lomb notunu korudu

RBC reiterates Bausch & Lomb stock rating on DED rival delay

Tracking Carl Icahn's 13F Report - Q4 2025 Update (NASDAQ:IEP)

Teladoc (TDOC) Surges 5.1%: Is This an Indication of Further Gains?

Toymaker Hasbro joins wave of companies suing U.S. government over IEEPA tariff payments

Bausch + Lomb stock hits 52-week high at $18.86

L’Oreal, Dyson, Bausch + Lomb become the latest to sue for Trump tariff refunds

H.C. Wainwright, Bausch & Lomb hisse hedefini 20 dolara yükseltti